Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Cantargia AB ( (SE:CANTA) ) is now available.
Cantargia announced that its management team will hold one-on-one meetings with investors and stakeholders at the Leerink Partners Global Healthcare Conference in Miami on March 11, 2026. Participation in this high-profile sector event underscores the company’s efforts to increase its visibility in the global healthcare investment community and could support strategic partnering and financing opportunities as it advances its antibody-based therapies in oncology and inflammatory disease.
The most recent analyst rating on (SE:CANTA) stock is a Buy with a SEK7.00 price target. To see the full list of analyst forecasts on Cantargia AB stock, see the SE:CANTA Stock Forecast page.
More about Cantargia AB
Cantargia AB is a Swedish biotechnology company developing antibody-based treatments for life-threatening diseases, built around targeting the protein IL1RAP, which is implicated in multiple cancers and inflammatory conditions. Its lead oncology candidate, nadunolimab (CAN04), is in clinical development primarily in combination with chemotherapy for pancreatic cancer, non-small cell lung cancer and triple-negative breast cancer, while its second program, CAN10 for serious autoimmune and inflammatory diseases, was acquired by Otsuka Pharmaceutical in 2025. Cantargia is listed on Nasdaq Stockholm under the ticker CANTA.
Average Trading Volume: 4,297,244
Technical Sentiment Signal: Buy
Current Market Cap: SEK1.46B
For detailed information about CANTA stock, go to TipRanks’ Stock Analysis page.